Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Feb;25(2):276–278. doi: 10.1111/j.1365-2125.1988.tb03303.x

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.

M S Lennard 1, J C McGourty 1, J H Silas 1
PMCID: PMC1386486  PMID: 3358891

Abstract

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of a single oral dose of prazosin has been studied in eight hypertensive patients (four extensive and four poor metabolisers). No significant differences between the two phenotypes were observed in either the area under the plasma prazosin concentration-time curve, the terminal half-life or the first-dose effect of prazosin.

Full text

PDF
276

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Elliott H. L., McLean K., Sumner D. J., Meredith P. A., Reid J. L. Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers. Clin Pharmacol Ther. 1981 Mar;29(3):303–309. doi: 10.1038/clpt.1981.40. [DOI] [PubMed] [Google Scholar]
  2. Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet. 1980 Jul-Aug;5(4):365–376. doi: 10.2165/00003088-198005040-00004. [DOI] [PubMed] [Google Scholar]
  3. Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560. doi: 10.1056/NEJM198212163072505. [DOI] [PubMed] [Google Scholar]
  4. Lewis R. V., Lennard M. S., Jackson P. R., Tucker G. T., Ramsay L. E., Woods H. F. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1985 Mar;19(3):329–333. doi: 10.1111/j.1365-2125.1985.tb02651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. McGourty J. C., Silas J. H., Lennard M. S., Tucker G. T., Woods H. F. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol. 1985 Dec;20(6):555–566. doi: 10.1111/j.1365-2125.1985.tb05112.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Oates N. S., Shah R. R., Idle J. R., Smith R. L. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther. 1983 Dec;34(6):827–834. doi: 10.1038/clpt.1983.257. [DOI] [PubMed] [Google Scholar]
  7. Reece P. A. Quantification of prazosin in plasma by high-performance liquid chromatography. J Chromatogr. 1980 Nov 14;221(1):188–192. doi: 10.1016/s0378-4347(00)81024-5. [DOI] [PubMed] [Google Scholar]
  8. Rosendorff C. Prazosin: severe side effects are dose-dependent. Br Med J. 1976 Aug 28;2(6034):508–508. doi: 10.1136/bmj.2.6034.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rubin P. C., Blaschke T. F. Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol. 1980 Jul;10(1):23–32. doi: 10.1111/j.1365-2125.1980.tb00498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Stokes G. S., Graham R. M., Gain J. M., Davis P. R. Influence of dosage and dietary sodium on the first-dose effects of prazosin. Br Med J. 1977 Jun 11;1(6075):1507–1508. doi: 10.1136/bmj.1.6075.1507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Taylor J. A., Twomey T. M., von Wittenau M. S. The metabolic fate of prazosin. Xenobiotica. 1977 Jun;7(6):357–364. doi: 10.3109/00498257709035794. [DOI] [PubMed] [Google Scholar]
  12. Wang T., Roden D. M., Wolfenden H. T., Woosley R. L., Wood A. J., Wilkinson G. R. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther. 1984 Mar;228(3):605–611. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES